Changes in Estimated Glomerular Filtration Rate in Naive HIV Patients with Fixed Drugs Combination Tenofovir Treatment in First 3 Months

Abstract

Ridwan Prasetyo, Usman Hadi, Muhammad Vitanata Arfijanto

The treatment HIV/AIDS uses ARVs, one of which is FDC tenofovir. FDC tenofovir is associated with changes in kidney function. This study aimed to determine changes in serum creatinine levels and eGFR in naïve HIV patients who received FDC tenofovir therapy for 3 months. This prospective longitudinal study included naïve HIV patients who received tenofovir. Serum creatinine levels and eGFR was measured before administration of tenofovir and after 3 months administration of tenofovir. Among 30 patients, the subject consisted 20 (66,7%) males and 10 (33.3%) females. The median age was 37 with range 17-57 years. The mean serum creatinine before tenofovir treatment 0.89 ± 0.25 mg/dL and after 3 months treatment mean ± SD 0.92 ± 0.28 mg/dL. The mean eGFR before administration of tenofovir treatment 89.37 ± 33.54 ml/min/1.73m2 and after 3 months the mean ± SD 88.31 ± 33.56 ml/min/1.73m2. There were no significant changes in serum creatinine and eGFR after 3 months administration of tenofovir (p = 0.441; p = 0.771, respectively). Serum creatinine and eGFR were not change after administration of tenofovir in naïve HIV patients.